HomeProductsBioactive CompoundsImmunology & InflammationThrombopoietin ReceptorAvatrombopag
Chemical structure of CAS 570406-98-3

Avatrombopag

In Stock•Starting at $10 for 50 mg•Purity ≥ 98%
CAS No.570406-98-3
MDL No.MFCD18633249
MFC29H34Cl2N6O3S2
MW649.70
InChI KeyOFZJKCQENFPZBH-UHFFFAOYSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
50 mg98%$10In Stock
100 mg98%$15In Stock
250 mg98%$23In Stock
1 g98%$57In Stock
5 g98%$190In Stock
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.570406-98-3
Product NameAvatrombopag

Biological Targets

MPL

Associated Conditions

Aplastic anemia·Thrombocytopenia·severe aplastic anemia·liver disease·hemorrhage·
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

Gastroenterology • Vol. 155, Issue 3 • 2018
PMID: 29778606DOI: 10.1053/j.gastro.2018.05.025

Pharmacokinetics, Pharmacodynamics, Pharmacogenomics, Safety, and Tolerability of Avatrombopag in Healthy Japanese and White Subjects.

Clinical pharmacology in drug development • Vol. 7, Issue 2 • 2018
PMID: 28339166DOI: 10.1002/cpdd.349

The Use of Thrombopoietin Receptor Agonists for Correction of Thrombocytopenia prior to Elective Procedures in Chronic Liver Diseases: Review of Current Evidence.

International journal of hepatology • Vol. 2016 • 2016
PMID: 27800187PMC: PMC5075314DOI: 10.1155/2016/1802932

Platelet Activation: The Mechanisms and Potential Biomarkers.

BioMed research international • Vol. 2016 • 2016
PMID: 27403440PMC: PMC4925965DOI: 10.1155/2016/9060143

Documentation

Similar Products